Live Biotherapeutics Drug Discovery Services for Metabolic Disease

Increasing evidence has shown probiotics contribute to reducing the symptoms of metabolic diseases, including obesity, diabetes mellitus, nonalcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and hepatic encephalopathy (HE). Creative Biolabs is an expert skilled in the development of probiotics. We offer a full range of probiotic development services, such as probiotics identification, safety tests, and host-microbe interaction tests.

Introduction of Metabolic Disease

Metabolic diseases are a group of diseases caused by abnormal metabolic processes, including diabetes, insulin resistance, diabetic ketoacidosis, hypertriglyceridemia, obesity, etc. These diseases disrupt the normal metabolic processes, involved in the metabolism disorders of amino acid, carbohydrate, fatty acid, purine, and pyrimidine. Metabolic diseases are very common. It is reported the prevalence of obesity is about 42.4% and the prevalence of severe obesity is approximately 9.2% in 2017-2018. Metabolic diseases are caused by inheritance, or by high-calorie diets, inappropriate lifestyle, and lack of exercise. In general, high-calorie diets and taking exercise may improve metabolic syndrome. Now, more and more studies have revealed that probiotics may be considered a complementary treatment for metabolic disorders.

Fig.1 Main comorbidities associated with the metabolic syndrome. (Pedro-Botet, 2018)Fig.1 Main comorbidities associated with the metabolic syndrome.1

Metabolic Disease and Probiotics


There is increasing evidence that obesity is associated with changes in the composition of gut microbiota in mice and humans. Because of the correlation between obesity and gut microbiota, it seems that probiotics may be an alternative for control weight, and oral some probiotics has been shown to reduce abdominal adiposity and body weight without the adverse effects.

Diabetes Mellitus

Insulin resistance is associated with increased intestinal permeability. These suggest some probiotics may have a positive impact on diabetes-related insulin resistance via regulating the barrier function of the intestinal mucosa. Probiotic administration has been indicated to reduce fasting glucose and decrease insulin resistance in patients with gestational diabetes.


NAFLD is the most prevalent chronic liver disease characterized by excessive fat accumulation in the liver of non-alcohol users. Probiotics have been shown to be a promising therapeutic option for the treatment of NAFLD.


CKD is a syndrome caused by a progressive decline in renal function. It is one of the risk factors for cardiovascular disease (CVD) and becomes a global health issue with a high economic cost. Interestingly, probiotics may be an alternative therapy to treat end-stage renal disease and attenuate uremia.


HE is a complex brain disease that causes temporary deterioration of brain function in patients with liver dysfunction. Currently, several studies have demonstrated that probiotics may act as a treatment option to manage HE. Besides, probiotics have also been indicated to prevent HE in patients with cirrhosis of the liver.


The hepatotoxicity of acetaminophen (APAP) is significantly regulated by gut microbiota. The hepatoprotective effects of probiotics and the underlying mechanisms have been revealed in different preclinical studies.


Modulation of the gut microbiota appears to be a possible strategy for the prevention and treatment of osteopenia and/or osteoporosis and possibly other bone alterations.


Changes or imbalances in the structure of intestinal flora are closely related to the occurrence and development of metabolic immune diseases such as hyperuricemia and gout, which can cause metabolic disorders and participate in the synthesis of purine metabolic enzymes and the release of inflammatory cytokines.


Alterations in gut microbiota are associated with common depression and anxiety in anorexia nervosa (AN) patients. An increase in mucin-degrading bacteria, Prevotella spp., has been reported in activity-based anorexia (ABA) mice, which can lead to changes in intestinal permeability.


  • Abundant experience in the development of next-generation probiotic
  • Customizable services to meet your special requirements
  • Advanced technologies
  • Short turnaround time

If you are interested in our services, please feel free to contact us for more details.


  1. Pedro-Botet, Juan, et al. "COSMIC project: consensus on the objectives of the metabolic syndrome in clinic." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy (2018): 683-697.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Live Biotherapeutic

Contact us

Copyright © 2024 Creative Biolabs. All Rights Reserved.

Inquiry Basket